Saturday, May 17, 2008

Help for Sun Damaged Skin


After spending my entire childhood playing tennis and swimming sans sunblock, my face has its share of pigment damage but worse, I’ve gotten several skin cancers. I’ve been employing many methods to make the five scars on my face less noticeable and was eager to try Photolagen-AGF ($89) manufactured by AminoGenesis Skin Care Products. The serum has a light, fruity scent due to the amino acids it contains and is designed to be used after washing your face but prior to the application of moisturizer. It glides on the face nicely and is quick to dry without any residue. It also passes the “first, do no harm” test—it hasn’t made my face break out or dry out.

The manufacturer says in clinical trials it reduced fine lines and wrinkles by 68% and furrow density by 46%. The patented product also is designed to “reverse damage caused by sun and natural aging, diminish appearance of age spots, reduce the appearance of dark circles, and improve skin firmness, texture and feel.” After three weeks use of this patented product, I’ve noticed a small but welcome improvement in my scars. Those lines appear smoother, less prominent. I have a slight tendency toward dark circles and those also appear diminished. My skin feels firmer too but I haven’t noticed any change to the pigment damage I’m hoping to correct. Overall, though, I’m pleased with the results and I’m happy to incorporate Photolagen-AGF into my daily regimen.

P.S. A note to the AminoGenesis marketing team: While the product name, Photolagen-AGF, kind of sounds like a Star Trek device, it doesn’t completely scare me off. However, the packaging looks to me like something you’d see on the shelf at the auto parts store. Something about the bronze and black lettering makes the product look industrial and made me think twice before I put in on my face. However, after Googling the product and studying the Aminogenesis website, I was assured enough that it was safe to use.

Photolagen-AGF was reviewed by Ellen Willson Hoover.

No comments: